<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390114</url>
  </required_header>
  <id_info>
    <org_study_id>1712469162</org_study_id>
    <nct_id>NCT03390114</nct_id>
  </id_info>
  <brief_title>Cognitive Behavioral Therapy to Treat Insomnia in Persons With HIV Infection</brief_title>
  <official_title>Internet-Based Cognitive Behavioral Therapy to Treat Insomnia in HIV: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this preliminary study is to determine the efficacy of an internet-based&#xD;
      treatment program for insomnia for HIV-infected persons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this pilot trial is to compare 10-week changes in Insomnia Severity&#xD;
      Index (ISI) scores in HIV-infected adults with clinically relevant insomnia severity and who&#xD;
      are already receiving virologically suppressive antiretroviral therapy (ART) and are then&#xD;
      randomized to either treatment with the SHUTi cognitive behavioral therapy program or to&#xD;
      Usual Care (UC). A total of 100 persons with HIV may be screened to identify the 32&#xD;
      participants to be enrolled and randomized into the pilot trial. These participants will be ≥&#xD;
      18 years old, have been receiving antiretroviral therapy with an HIV viral load &lt; 75&#xD;
      copies/mL within three months of the Entry Visit, and have an ISI score ≥ 15 within three&#xD;
      months of the Entry Visit. These participants will be randomized 1:1 (stratified by age &lt;40&#xD;
      vs. ≥ 40 years) to either insomnia treatment with the SHUTi cognitive behavioral therapy&#xD;
      program (N=16) or usual care (N=16).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>10-week, randomized, controlled, single-blinded, two-arm, parallel group, pilot trial at a single center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The primary investigator is blinded to the treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in the Insomnia Severity Index (ISI) score as measured by questionnaire. The ISI score ranges from 0 to 28 with higher scores indicating greater severity in insomnia symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>SHUTi Cognitive Behavioral Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SHUTi</intervention_name>
    <description>SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.</description>
    <arm_group_label>SHUTi Cognitive Behavioral Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-1 infection, documented by both: (1) any licensed rapid HIV test or HIV enzyme&#xD;
             test kit at any time prior to study entry and (2) by at least one detectable HIV-1&#xD;
             antigen or at least one detectable plasma HIV-1 RNA viral load.&#xD;
&#xD;
          2. Age equal to or greater than 18 years.&#xD;
&#xD;
          3. Ongoing receipt of antiretroviral therapy of any kind for at least 3 months prior to&#xD;
             the Entry Visit.&#xD;
&#xD;
          4. HIV-1 RNA level &lt; 75 copies/mL obtained during routine clinical care within 90 days of&#xD;
             the Entry Visit.&#xD;
&#xD;
             NOTE: There are no CD4 cell count eligibility criteria for this trial.&#xD;
&#xD;
          5. ISI score ≥ 15&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to complete written, informed consent.&#xD;
&#xD;
          2. Incarceration at the time of any study visit.&#xD;
&#xD;
          3. Active suicidality, as determined by the patient's HIV provider or social worker&#xD;
             following a positive response (1, 2, or 3) to PHQ-9 Item #9&#xD;
&#xD;
          4. Diagnosed vascular disease (documented history of angina pectoris, coronary disease,&#xD;
             peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise&#xD;
             known atherosclerotic disease).&#xD;
&#xD;
          5. History of congestive heart failure, even if currently compensated.&#xD;
&#xD;
          6. Diagnosed disease or process, besides HIV infection, associated with increased&#xD;
             systemic inflammation (including, but not limited to, systemic lupus erythematosis,&#xD;
             inflammatory bowel diseases, other collagen vascular diseases).&#xD;
&#xD;
             Note: Hepatitis B or C co-infections are NOT exclusionary&#xD;
&#xD;
          7. Known or suspected malignancy requiring systemic treatment within 180 days of the&#xD;
             Entry Visit.&#xD;
&#xD;
             NOTE: Localized treatment for skin cancers is not exclusionary.&#xD;
&#xD;
          8. Uncontrolled hyperthyroidism or hypothyroidism, defined as TSH values outside of the&#xD;
             local reference range on most recent clinical assessment.&#xD;
&#xD;
          9. Last known clinic-based estimated glomerular filtration rate (eGFR) &lt; 50&#xD;
             mL/min/1.73m2. (calculated from the 2009 CKD-EPI equation).&#xD;
&#xD;
         10. Uncontrolled diabetes defined as the last known clinic-based Hgb A1C &gt; 8.0 g/dL.&#xD;
&#xD;
         11. Last known clinic-based total cholesterol &gt; 240 mg/dL.&#xD;
&#xD;
         12. Therapy for serious medical illnesses within 14 days prior to screening.&#xD;
&#xD;
             Note: Therapy for serious medical illnesses that overlaps with a main study visit will&#xD;
             result in postponement of that study visit until the course of therapy is completed;&#xD;
             postponement outside of the allowed study visit timeframe will result in study&#xD;
             discontinuation.&#xD;
&#xD;
         13. Pregnancy or breastfeeding during the course of the study.&#xD;
&#xD;
         14. Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids&#xD;
             (of any dose), or anabolic steroids at the Entry Visit.&#xD;
&#xD;
             Note: Physiologic testosterone replacement therapy or topical steroids is not&#xD;
             exclusionary. Inhaled/nasal steroids are not exclusionary as long as the participant&#xD;
             is not also receiving HIV protease inhibitors.&#xD;
&#xD;
         15. Active drug use or dependence that, in the opinion of the investigator, would&#xD;
             interfere with adherence to study requirements.&#xD;
&#xD;
         16. History of schizophrenia, bipolar disorder, or dementia.&#xD;
&#xD;
             NOTE: Depression is not exclusionary as long as the severity of depression does impede&#xD;
             ability to perform the required study procedures.&#xD;
&#xD;
         17. Musculoskeletal or neurologic disorders that impede ability to perform the required&#xD;
             study procedures.&#xD;
&#xD;
         18. History of sleep apnea or restless leg syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir K Gupta, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Diseases Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <results_first_submitted>January 29, 2021</results_first_submitted>
  <results_first_submitted_qc>February 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samir K Gupta, MD, MS</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be made available to other researchers. These include demographics, medical history/medication history, ISI scores, and changes in ISI scores by study arm.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will become available within 30 days of completion of final statistical analysis. There is no expiration of data availability.</ipd_time_frame>
    <ipd_access_criteria>Please contact the study PI, Dr. Samir Gupta, for specific details on data availability.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03390114/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03390114/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SHUTi Cognitive Behavioral Therapy</title>
          <description>SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.&#xD;
SHUTi: SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SHUTi Cognitive Behavioral Therapy</title>
          <description>SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.&#xD;
SHUTi: SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.2" spread="11.4"/>
                    <measurement group_id="B2" value="47.0" spread="14.7"/>
                    <measurement group_id="B3" value="46.6" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insomnia Severity Index</title>
        <description>Change in the Insomnia Severity Index (ISI) score as measured by questionnaire. The ISI score ranges from 0 to 28 with higher scores indicating greater severity in insomnia symptoms.</description>
        <time_frame>10 weeks</time_frame>
        <population>Those who completed both pre and post assessments</population>
        <group_list>
          <group group_id="O1">
            <title>SHUTi Cognitive Behavioral Therapy</title>
            <description>SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.&#xD;
SHUTi: SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index</title>
          <description>Change in the Insomnia Severity Index (ISI) score as measured by questionnaire. The ISI score ranges from 0 to 28 with higher scores indicating greater severity in insomnia symptoms.</description>
          <population>Those who completed both pre and post assessments</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="9.4"/>
                    <measurement group_id="O2" value="-3.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SHUTi Cognitive Behavioral Therapy</title>
          <description>SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.&#xD;
SHUTi: SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samir K. Gupta, MD, MS</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>3172747926</phone>
      <email>sgupta1@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

